Tata Elxsi Launches a Global Technology Centre for Medical Devices from Bayer

Pune:  Tata Elxsi, a global leader in design and technology services, today announced the inauguration of the ‘Bayer Development Centre in Radiology’ at Tata Elxsi, Pune, India. The centre is designed to co-develop with Bayer, a leader in key areas of Radiology, advanced radiology devices and technology that enable early and accurate diagnosis and treatment of critical illnesses, supporting Bayer’s global mission to bring innovative, safe, and compliant solutions to patients and clinical staff worldwide.

This centre will provide a wide range of engineering for complex radiology devices, with an initial focus on Molecular Imaging. The facility’s integrated approach, which combines design, development, and validation, the centre will help accelerate time-to-market, enhance cost efficiency, and help deliver new technology to market fast, efficiently, and at an optimized cost, while meeting highest regulatory compliance standards.

This collaboration leverages Tata Elxsi’s healthcare engineering expertise and the strength of the Tata and India ecosystems—enabling access to advanced labs, regulatory partnerships, and specialised technology talent. This creates a scalable foundation for innovation and strengthens Bayer’s ability to deliver radiology solutions across multiple geographies, including the US and EU.

Dr. Konstanze Diefenbach, Head of Research & Development, Radiology, Bayer, commented: “Bayer is committed to innovative products and high-quality services in diagnostic imaging, and device innovation plays a critical role in delivering precision and safety in patient care. This new centre gives us direct access to specialised engineering capabilities through Tata Elxsi, enabling us to accelerate our pipeline of advanced radiology devices while maintaining the quality and reliability that healthcare providers expect from Bayer.”

Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This centre is more than an engineering hub—it is where Bayer’s radiology vision meets Tata Elxsi’s design, AI/ML, and regulatory expertise. Our teams will work together to translate ideas into devices that address real-world diagnostic challenges, with the assurance of safety, compliance, and global scalability.”

Related Posts

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna: In a significant ruling that could have far-reaching implications for NDPS drug-related prosecutions involving common pharmaceutical compounds, the Patna High Court has held that Phenothiazine and Promethazine do not…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines